文献速递基础与转化研究临床试验与 GCP流行病学与生物统计

巨细胞病毒血清状态与抗PD-1免疫检查点阻断后生存改善及毒性延迟发生相关

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
PubMed 文献 · Nat Med · 2025-04-23

在341例前瞻性招募的黑色素瘤免疫检查点阻断患者中,CMV+转移性黑色素瘤患者淋巴细胞计数更高、中性粒细胞与淋巴细胞比值更低且CD8+ T细胞基因表达存在差异;CMV+单药抗PD-1治疗者总生存改善(HR 0.37,P<0.01),且6个月3级以上免疫相关不良事件累积发生率降低(0.30 vs 0.52,P=2.2×10⁻⁵)。

要点

  • CMV+单药抗PD-1ICB患者总生存改善,HR 0.37,P<0.01
  • CMV+患者6个月3级以上irAE累积发生率0.30 vs 0.52,P=2.2×10⁻⁵
  • TBX21表达预测总生存,HR 0.62,P=0.026

核心结论

  • CMV感染与黑色素瘤发展(依BRAF状态)及ICB应答存在交互作用,并显示对严重ICB免疫相关不良事件具有保护作用。

研究设计与样本

  • 前瞻性招募341例接受免疫检查点阻断(ICB)治疗的黑色素瘤患者。
  • 非黑色素瘤ICB受者58例用于复制分析。
  • 与UK Biobank对照比较CMV血清阳性率。

主要发现

  • CMV+转移性黑色素瘤患者淋巴细胞计数更高、中性粒细胞与淋巴细胞比值更低且CD8+ T细胞基因表达存在差异。
  • 联合抗CTLA-4/抗PD-1 ICB受者总生存与CMV血清状态无关(CMV+死亡HR 1.02,P=0.92)。
  • CMV+单药抗PD-1 ICB受者总生存改善(CMV+死亡HR 0.37,P<0.01),CMV+辅助单药抗PD-1 ICB受者复发HR 0.19,P=0.03。
  • CMV+患者6个月3级以上免疫相关不良事件累积发生率降低(0.30 vs 0.52,P=2.2×10⁻⁵),结肠炎(P=7.8×10⁻⁴)和肺炎(P=0.028)发生率更低,非黑色素瘤ICB受者中复制(n=58,P=0.044)。
  • TBX21表达预测总生存(HR 0.62,P=0.026);转移性黑色素瘤患者CMV血清阳性率低于UK Biobank对照(OR 0.52,P=1.8×10⁻⁴);BRAF突变型MM患者CMV+可能性更低(OR=2.2,P=0.0054),CMV-患者BRAF野生型MM发病早9年(P=1.3×10⁻⁴)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV+ patients with metastatic melanoma (MM) have higher lymphocyte counts, reduced neutrophil to lymphocyte ratio and divergent CD8+ T cell gene expression. Combination anti-CTLA-4/anti-PD-1 ICB, but not single-agent anti-PD-1 ICB, induces cytotoxicity and CMV-associated gene expression in CD8+ T cells from CMV- patients. Correspondingly, overall survival was independent of CMV serostatus in combination anti-CTLA-4/anti-PD-1 ICB recipients (CMV+ hazard ratio for death: 1.02, P = 0.92), whereas CMV+ single-agent anti-PD-1 ICB recipients had improved overall survival (CMV+ hazard ratio for death: 0.37, P < 0.01), a finding also seen in CMV+ adjuvant single-agent anti-PD-1 ICB recipients (CMV+ hazard ratio for recurrence: 0.19, P = 0.03). We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8+ T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV+ patients unexpectedly show reduced cumulative incidence of grade 3+ immune-related adverse events at 6 months (0.30 versus 0.52, P = 2.2 × 10-5), with lower incidence of colitis (P = 7.8 × 10-4) and pneumonitis (P = 0.028), an effect replicated in non-melanoma ICB recipients (n = 58, P = 0.044). Finally, we find reduced CMV seropositivity rates in patients with MM compared with UK Biobank controls (odds ratio: 0.52, P = 1.8 × 10-4), indicating CMV seropositivity may protect against MM. Specifically, patients with BRAF-mutated MM are less likely to be CMV+ (odds ratio = 2.2, P = 0.0054), while CMV- patients present 9 yr earlier with BRAF wild-type MM (P = 1.3 × 10-4). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Milotay G, Little M, Watson RA, et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med. 2025. PMID: 40269332. doi:10.1038/s41591-025-03647-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。